Aripiprazole Tablet
Product Images NDC 29300-180

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 29300-180). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (1bd98187 Fd05 4ff3 8087 E427722d7061 01)

Chemical structure of Aripiprazole, showing the arrangement of chlorophenyl, piperazine, and quinolinone groups connected by a propoxy linker.*

FDA Label Image

Figure 1: The Effects Of Other Drugs On Aripiprazole Pharmacokinetics (1bd98187 Fd05 4ff3 8087 E427722d7061 02)

A pharmacokinetic chart illustrating the effect of other drugs on Aripiprazole's plasma levels, showing fold changes and 90% confidence intervals for AUC and Cmax relative to a reference without interacting drugs. The chart categorizes interacting drugs as CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others, including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Image (1bd98187 Fd05 4ff3 8087 E427722d7061 03)

A pharmacokinetic chart showing the effect of various drugs on Aripiprazole measured by dehydro-aripiprazole fold change and 90% confidence intervals. It compares AUC and Cmax values relative to a reference without interacting drugs for CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs including valproate, lithium, and lorazepam.*

FDA Label Image

Image (1bd98187 Fd05 4ff3 8087 E427722d7061 04)

A forest plot chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The horizontal axis represents change relative to reference without interacting drug. The chart indicates pharmacokinetic parameters such as AUC, Cmax, INR, and DM/DRP for each drug.*

FDA Label Image

Image (1bd98187 Fd05 4ff3 8087 E427722d7061 05)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing the fold change in AUC and Cmax for various special populations compared to reference. Categories include CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis represents change relative to reference from 0.5 to 3.0, with plotted points and confidence intervals illustrating differences in drug exposure across these populations.*

FDA Label Image

Image (1bd98187 Fd05 4ff3 8087 E427722d7061 06)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing fold changes in AUC and Cmax relative to reference under various conditions including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis represents change relative to reference, with data points and confidence intervals plotted for each category.*

FDA Label Image

Image (1bd98187 Fd05 4ff3 8087 E427722d7061 07)

A Kaplan-Meier curve graph showing the proportion with relapse over days from randomization for Aripiprazole versus placebo groups. The solid line represents Aripiprazole and the dashed line placebo, with lower relapse proportions in the Aripiprazole group. A table below shows the number of subjects at risk over time for each group.*

FDA Label Image

Image (1bd98187 Fd05 4ff3 8087 E427722d7061 08)

A line graph comparing the proportion of relapse over time between Aripiprazole and placebo groups. The x-axis shows days from randomization up to 182 days, and the y-axis represents the proportion with relapse from 0.0 to 1.0. Two lines plot relapse over time: a solid line for Aripiprazole and a dashed line for placebo. Numbers of subjects at risk are listed below the x-axis at various time points for each group.*

FDA Label Image

Image (1bd98187 Fd05 4ff3 8087 E427722d7061 09)

A Kaplan-Meier curve depicting the proportion of subjects with relapse over 364 days from randomization, comparing Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Number of subjects at risk is shown below the x-axis at multiple time points.*

FDA Label Image

Image (1bd98187 Fd05 4ff3 8087 E427722d7061 10)

FDA Label Image

Image (1bd98187 Fd05 4ff3 8087 E427722d7061 11)

FDA Label Image

Aripiprazole Tablets, Usp 2 mg (30's count)

Aripiprazole 2 mg tablets label showing the dosage form as oral tablets. The label includes the NDC code 29300-175-13, indicates the strength of 2 mg per tablet, and states the package contains 30 tablets. It is manufactured by Unichem Laboratories Ltd. in India and labeled by Unichem Pharmaceuticals (USA), Inc. Storage instructions and a warning to keep out of reach of children are also present.*

FDA Label Image

Aripiprazole Tablets, Usp 5 mg (30's count)

Label for Aripiprazole Tablets USP 5 mg oral tablets by Unichem Pharmaceuticals (USA), Inc. The label shows NDC 29300-176-13, quantity of 30 tablets, and states pharmacist dispensing instructions. Storage instructions specify 20° to 25°C. Manufacturer information includes Unichem Laboratories Ltd., India.*

FDA Label Image

Aripiprazole Tablets, Usp 10 mg (30's count)

Label for Aripiprazole Tablets, USP 10 mg, showing a package of 30 oral tablets. The label includes the NDC code 29300-177-13 and states that the tablets contain 10 mg of Aripiprazole. It is manufactured by Unichem Laboratories Ltd. in India and labeled by Unichem Pharmaceuticals (USA), Inc. Directions emphasize pharmacist dispensation and storage at controlled room temperature.*

FDA Label Image

Aripiprazole Tablets, Usp 15 mg (30's count)

Aripiprazole Tablets USP 15 mg label from Unichem Pharmaceuticals (USA), Inc. The label displays the NDC number 29300-178-13 and indicates a package size of 30 tablets. It includes storage instructions, the manufacturer details (Unichem Laboratories Ltd., India), and the labeler location (Unichem Pharmaceuticals USA, Inc., New Jersey). The label notes the medication is Rx only and emphasizes keeping drugs out of reach of children.*

FDA Label Image

Aripiprazole Tablets, Usp 20 mg (30's count)

Aripiprazole Tablets, USP 20 mg oral tablet label with NDC 29300-179-13 by Unichem Pharmaceuticals (USA), Inc. The label includes storage instructions, pharmacist dispensing note, and identifies the manufacturer as Unichem Laboratories Ltd., India, and Unichem Pharmaceuticals (USA), Inc. The package contains 30 tablets.*

FDA Label Image

Aripiprazole Tablets, Usp 30 mg (30's count)

Aripiprazole 30 mg tablets, USP, oral dosage form, supplied in a bottle containing 30 tablets. The label includes storage instructions and indicates the product is manufactured by Unichem Laboratories Ltd. in India and labeled by Unichem Pharmaceuticals (USA), Inc. The label features the NDC 29300-180-13 and highlights that the medication is prescription only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.